QUEBEC , Feb. 5, 2025 /PRNewswire/ - Holder of an innovative diagnostic support technology, recognized by the Food and Drug Administration (FDA) as a major scientific breakthrough, diaMentis unveils unprecedented results for the optimization and acceleration of mental illness diagnosis, marking a significant turning point for the Quebec -based company. Highlighted in the peer-reviewed international journal Biomedical Signal Processing and Control , diaMentis' study reveals previously unexplored areas of the retinal signal, and identifies new key factors to better differentiate mental disorders.
This breakthrough will notably enable much more efficient diagnosis of mental illnesses, including schizophrenia and type 1 bipolar disorder. These results could be pivotal in driving a major paradigm shift in mental health management, significantly reducing the overall burden of institutional and community care. Provided that the necessary additional capital and resources are secured, diaMentis' innovative diagnostic support technology could be applied to other therapeutic fields that also need modernization.
What the study reveals The study highlights the relevance of high-density retinal signals for deciphering biosignatures, as described in diaMentis' patent portfolio and patent applications. The study confirms the exceptional performances of diaMentis' prediction models and its patented RSPA® (retinal signal processing and analysis) concept. This system uses high-density retinal .